Amylin (AMLN +47.6%) soars to $22.71 after Bloomberg reports the diabetes drugmaker turned down...


Amylin (AMLN +47.6%) soars to $22.71 after Bloomberg reports the diabetes drugmaker turned down a $22/share bid from Bristol-Myers Squibb (BMY) earlier this year. It's added Bristol-Myers hasn't approached Amylin since the rejection, and the latter company is focused on finding an international marketing partner for its products.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs